Related Experiment Videos
Cardiovascular complications in acromegaly
G Vitale1, R Pivonello, G Lombardi
1Department of Molecular and Clinical Endocrinology, School of Medicine, Federico II University of Naples, Naples, Italy.
Minerva Endocrinologica
|July 30, 2004
Summary
Acromegaly, caused by excess growth hormone (GH) and insulin-like growth factor-I (IGF-I), significantly increases cardiovascular risks. Effective treatment can improve heart function and reduce cardiac complications in patients.
Area of Science:
- Endocrinology
- Cardiology
- Internal Medicine
Background:
- Acromegaly, a condition of excess growth hormone (GH) and insulin-like growth factor-I (IGF-I), is associated with increased cardiovascular morbidity and mortality.
- GH and IGF-I excess lead to a specific cardiomyopathy, characterized initially by a hyperkinetic syndrome.
Purpose of the Study:
- To describe the cardiac manifestations of acromegaly.
- To highlight the impact of GH/IGF-I excess on cardiac structure and function.
- To emphasize the importance of cardiac evaluation and the potential benefits of treatment.
Main Methods:
- The abstract does not specify methods, but discusses established clinical observations and pathophysiology.
- Review of literature on acromegaly and its cardiovascular complications.
Main Results:
- Acromegaly frequently causes concentric biventricular hypertrophy and diastolic dysfunction, potentially progressing to impaired systolic function and heart failure.
- Cardiac rhythm and valve abnormalities are also observed.
- Comorbidities like hypertension and diabetes worsen acromegalic cardiomyopathy.
Conclusions:
- Effective therapy suppressing GH/IGF-I may reduce left ventricular mass and improve cardiac function.
- Comprehensive cardiac assessment is essential for managing patients with acromegaly.